Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

被引：0
|
作者：
Guarino, Michael J.
Starodub, Alexander
Masters, Gregory A.
Heist, Rebecca Suk
Messersmith, Wells A.
Bardia, Aditya
Ocean, Allyson J.
Thomas, Sajeve Samuel
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
机构：
[1] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA
[2] Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA
[3] Helen F Graham Canc Ctr, Newark, DE USA
[4] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[5] Univ Colorado Canc Ctr, Aurora, CO USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[7] Weill Cornell Med Coll, New York, NY USA
[8] Univ Florida, Windermere, FL USA
[9] Immunomedics Inc, Morris Plains, NJ USA
[10] Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2504
引用
收藏
页数：1
相关论文
共 50 条
  • [21] SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results
    Starodub, Alexander N.
    Ocean, Allyson J.
    Shah, Manish A.
    Vahdat, Linda T.
    Chuang, Ellen
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Govindan, Serengulam V.
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Starodub, Alexander N.
    Shah, Nikita C.
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Guarino, Michael
    Abramson, Vandana
    Juric, Dejan
    Tolaney, Sara M.
    Berlin, Jordan
    Messersmith, Wells A.
    Ocean, Allyson J.
    Wegener, William A.
    Maliakal, Pius
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2141 - +
  • [23] Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib
    Goldenberg, D. M.
    Cardillo, T. M.
    Govindan, S. V.
    Zalath, M.
    Arrojo, R.
    Sharkey, R. M.
    CANCER RESEARCH, 2016, 76
  • [24] Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
    Sharkey, Robert M.
    McBride, William J.
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Wang, Yang
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2015, 21 (22) : 5131 - 5138
  • [25] Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.
    Starodub, Alexander N.
    Ocean, Allyson J.
    Guarino, Michael J.
    Chuang, Ellen
    Shah, Manish A.
    Tagawa, Scott
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Wegener, William A.
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [26] Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
    Heist, Rebecca Suk
    Guarino, Michael J.
    Masters, Gregory
    Purcell, W. Thomas
    Starodub, Alexander N.
    Horn, Leora
    Scheff, Ronald J.
    Bardia, Aditya
    Messersmith, Wells A.
    Berlin, Jordan
    Ocean, Allyson J.
    Govindan, Serengulam V.
    Maliakal, Pius
    Mudenda, Boyd
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2790 - +
  • [27] Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
    Gray, Jhanelle E.
    Heist, Rebecca S.
    Starodub, Alexander N.
    Camidge, D. Ross
    Kio, Ebenezer A.
    Masters, Gregory A.
    Purcell, W. Thomas
    Guarino, Michael J.
    Misleh, Jamal
    Schneider, Charles J.
    Schneider, Bryan J.
    Ocean, Allyson
    Johnson, Tirrell
    Gandhi, Leena
    Kalinsky, Kevin
    Scheff, Ronald
    Messersmith, Wells A.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Mudenda, Boyd
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5711 - 5719
  • [28] Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
    Cardillo, Thomas M.
    Sharkey, Robert M.
    Rossi, Diane L.
    Arrojo, Roberto
    Mostafa, Ali A.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3405 - 3415
  • [29] Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Zalath, Maria
    Mostafa, Ali
    Arrojo, Roberto
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2016, 76
  • [30] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
    Bardia, A.
    Messersmith, W. A.
    Kio, E. A.
    Berlin, J. D.
    Vahdat, L.
    Masters, G. A.
    Moroose, R.
    Santin, A. D.
    Kalinsky, K.
    Picozzi, V
    O'Shaughnessy, J.
    Gray, J. E.
    Komiya, T.
    Lang, J. M.
    Chang, J. C.
    Starodub, A.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Wegener, W. A.
    Goswami, T.
    Ocean, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
12345